Candel Therapeutics, Inc. Income Statement
CADL|3 years of annual SEC 10-K data (FY2021-FY2023)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Revenue increased 0.0% from FY2021 to FY2022.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Revenue | - | $125.0K | $125.0K |
| SG&A Expense | $13.9M | $10.7M | $5.2M |
| R&D Expense | $24.5M | $15.2M | $8.8M |
| Operating Income | -$38.4M | -$25.7M | -$13.8M |
| Interest Expense | -$2.6M | - | - |
| Income Tax | $0 | $0 | - |
| Net Income | -$37.9M | -$36.1M | -$17.7M |
| EPS (Basic) | -$0.65 | -$1.91 | - |
| EPS (Diluted) | -$0.65 | -$1.91 | -$1.52 |
| Shares Outstanding | 28.9M | 28.7M | 11.6M |
| Operating Margin | - | -20580.8% | -11048.0% |
| Profit Margin | - | -28899.2% | -14144.0% |